2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin
2010
Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer 2010, 9: 311-314. PMID: 21208846, PMCID: PMC3088086, DOI: 10.3816/ccc.2010.n.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPilot ProjectsSalvage TherapySurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsExtensive liver metastasesRefractory solid tumorsLiver metastasesTotal bilirubinSolid tumorsBaseline serum total bilirubinHepatic arterial infusion (HAI) oxaliplatinMedian Child-Pugh scoreAdvanced refractory malignanciesGrade 1 fatigueMedian total bilirubinRegional hepatic therapySystemic anticancer agentsChild-Pugh scoreCommon side effectsSerum total bilirubinPilot clinical trialElevated bilirubinLiver involvementPartial responseHepatic insufficiencyMedian ageRefractory malignanciesClinical trialsDisease progressionHepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver
Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver. American Journal Of Clinical Oncology 2010, 33: 474-480. PMID: 19935383, DOI: 10.1097/coc.0b013e3181b4b065.Peer-Reviewed Original ResearchConceptsHepatic arterial chemoembolizationOcular melanoma metastaticProgression-free survival durationMedian OS durationOverall survivalLactate dehydrogenase levelsMelanoma metastaticRadiologic responseLiver involvementSurvival durationOS durationDehydrogenase levelsResponse rateBaseline lactate dehydrogenase levelsHigher lactate dehydrogenase levelsMedian overall survivalTumor response rateHepatic artery chemoembolizationShorter overall survivalStable diseaseDisease stabilizationProgressive diseaseArterial chemoembolizationMost patientsPartial response
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survival
2008
Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization
Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization. Journal Of Vascular And Interventional Radiology 2008, 19: 145-151. PMID: 18192482, DOI: 10.1016/j.jvir.2007.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiographyBrachytherapyCarcinoma, NeuroendocrineChemoembolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMicrospheresMiddle AgedRetrospective StudiesTime FactorsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsNeuroendocrine hepatic metastasesHepatic metastasesEmbolization proceduresRadiation-induced liver diseaseYttrium-90 resin microspheresMetastatic neuroendocrine carcinomaCohort of patientsHepatic arterial embolizationTime of diagnosisReasonable therapeutic optionMedian survival timeHepatic artery radioembolizationHepatic progressionDisease stabilizationArterial embolizationPartial responseProgressive diseaseMedian ageLiver diseaseTherapeutic optionsStudy criteriaMicrosphere infusionNeuroendocrine carcinomaSurvival timeMicrosphere radioembolization
2007
Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases
Kamat PP, Gupta S, Ensor JE, Murthy R, Ahrar K, Madoff DC, Wallace MJ, Hicks ME. Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases. CardioVascular And Interventional Radiology 2007, 31: 299-307. PMID: 17922160, DOI: 10.1007/s00270-007-9186-3.Peer-Reviewed Original ResearchConceptsProgression-free survivalHepatic arterial embolizationGastrointestinal stromal tumorsOverall survivalNeuroendocrine tumorsRadiologic responseArterial embolizationDisease stabilizationLiver involvementLiver metastasesMajor complicationsLonger progression-free survivalLiver tumor burdenMedian overall survivalMetastatic neuroendocrine tumorsProcedure-related mortalityMajority of patientsManagement of patientsAdditional risk factorsHigh response rateStable diseaseSymptom palliationPartial responsePerformance statusProgressive disease